Two inSPire2026 posters detail how health system specialty pharmacy teams support patients with ATTR-CM.
|Articles|September 30, 2015
Supplements and Featured Publications
- Management of Advanced/Metastatic Melanoma: New and Emerging Treatment Pathways, Therapies, and Chal
- Volume 21
- Issue 12 Suppl
Post Test: Management of Advanced/Metastatic Melanoma: New and Emerging Treatment Pathways, Therapies, and Challenges
Advertisement
Pharmacy Credit
Instructions for Receiving Continuing Pharmacy Education (CPE) Credit: Testing and Grading Information
This lesson is free online; receive instant grading and download your CE statement of credit at
Testing and Grading Directions
- Each participant evaluating the activity and achieving a passing grade of 70% or higher on the online posttest will receive a CE statement of credit stating the number of credits earned.
- Participants receiving a failing grade on the exam will be notified and permitted to take 1 reexamination at no cost.
Articles in this issue
Advertisement
Related to this article
Patients with Sjögren disease diagnosed over a year after symptom onset had 2.3 times the odds of moderate or greater disease activity, a US survey found.
An estimated 44,052 sports eye injuries were treated in 2025 and 1262 pickleball eye injuries in 2024; 99% of lawnmower eye injuries were at home.
Teva's Weltruza, a once-monthly subcutaneous olanzapine injection, requires no loading doses, oral supplementation, or postinjection monitoring.
Population growth and aging, not rising age-standardized rates, drives the increase, with underlying causes varying widely by age and region.
The FDA approves atezolizumab with a fluoropyrimidine and oxaliplatin as adjuvant therapy for stage III dMMR colon cancer based on the ATOMIC trial.
Washington, DC, clinicians shared how order sets, pharmacist-led dosing, and better handoffs can close iron deficiency gaps in heart failure care.
Michael Mina, MD, PhD, explains Invivyd's accelerated approval path for VYD2311 and how it could change the timing of COVID-19 protection.
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves IV, Subcutaneous Atezolizumab for dMMR Colon Cancer
2
5 Things to Know if Retatrutide Is Classified as a Biologic
3
FDA Approves Once-Monthly Subcutaneous Olanzapine for Schizophrenia
4
Bumetanide Nasal Spray Targets Heart Failure Edema Before IV
5